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Background: Concurrent personality disorder (PD) and substance use disorder (SUD) are 
common in clinical practice. However, SUD is the main criterion for study exclusion in most 
psychotherapeutic studies of PD. As a result, data on treatment outcomes in patients with con-
current PD/SUD are scarce.
Methods: The study sample consisted of 51 patients diagnosed with severe PD and admit-
ted for psychotherapeutic treatment as a part of routine mental health care. All patients were 
diagnosed with PD according to the Structured Clinical Interview for PD. Patients were fur-
ther assessed (DSM-IV diagnostic criteria) to check for the presence of concurrent SUD, with 
28 patients diagnosed with both disorders (PD-SUD). These 28 cases were then compared to 
the 23 patients without SUD (PD-nSUD) in terms of psychiatric hospitalizations and psychiatric 
emergency room (ER) visits before and during the 6-month therapeutic intervention and every 
6 months thereafter for a total of 36 months.
Results: The baseline clinical characteristics correspond to a sample of PD patients (78% met 
DSM-IV criteria for borderline PD) with poor general functioning and a high prevalence of sui-
cide attempts and self-harm behaviors. Altogether, the five outcome variables – the proportion 
and the number of psychiatric inpatient admissions, the number of days hospitalized, and the 
proportion and the number of psychiatric ER visits – improved significantly during the treat-
ment period, and this improvement was maintained throughout the follow-up period. Although 
PD-SUD patients had more psychiatric hospitalizations and ER visits than PD-nSUD patients 
during follow-up, the differences between these two groups remained stable over the study 
period indicating that the treatment was equally effective in both groups.
Conclusion: Specialized psychotherapy for severe PD can be effectively applied in patients 
with concurrent PD-SUD under usual practice conditions. These findings suggest that exclusion 
of patients with dual disorders from specialized treatments is unjustified.
Keywords: personality disorder, substance use disorder, borderline personality disorder, dual 
disorders, psychotherapy, pragmatic clinical study
Background
Numerous studies have shown that the co-occurrence of personality disorders (PDs) 
with substance use disorders (SUDs) is high but variable in both the general population 
and in clinical populations. Among individuals in the general population with SUD, 
it is estimated that from 29% to 48% also have PD. Conversely, among individuals 
in the general population with PD, ~7%–16% are believed to have concurrent SUD.1 
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By contrast, 34%–91% of treatment-seeking patients with 
SUD also have PD, and up to 84% of patients seeking treat-
ment for PD also have concurrent SUD.2–5 The co-occurrence 
of PD with SUD, especially when impulsivity predominates, 
negatively impacts the clinical course and outcomes of 
SUD.3,6–8 Moreover, some evidence suggests that concurrent 
SUD may render PD psychopathology more serious, although 
the evidence is not as strong.5
Studies that have evaluated the efficacy of psychotherapy 
in patients with SUD and comorbid PD9–11 are sparse and 
often controversial.12,13 In contrast, a variety of different 
psychotherapeutic interventions have been proven effec-
tive for PD in several prospective studies,14–16 and similar 
outcomes are achieved regardless of whether the interven-
tions are applied in outpatient settings,17–21 day hospital 
programs,22–27 or inpatient programs.28 However, many of 
the studies that have investigated the efficacy of PD psy-
chotherapy have excluded PD patients with concurrent SUD 
(PD-SUD).18,20,25,29 In other studies, not all patients with 
dual PD-SUD were excluded from specialized treatments, 
although the proportion of patients excluded can be highly 
variable. More restrictive studies exclude 70%–94% of PD-
SUD patients,17,21,22,24 while less restrictive studies exclude 
less than 50% of the PD-SUD patients.19,26,27,30
Overall, the available evidence14,31,32 indicates that SUD 
is a barrier for access to specialized PD treatment. PD-SUD 
patients are typically excluded for both methodological31 and 
clinical14 reasons, a phenomenon that is evident in random-
ized controlled trials (RCT), which are often designed to 
increase study feasibility and to decrease response hetero-
geneity. However, by applying highly restrictive eligibility 
criteria, such studies may yield results whose external validity 
is low, due in part to sample bias. The same is true for PD psy-
chotherapy studies, in which SUD is the leading criterion for 
study exclusion.31 Such studies tend to recruit “pure” rather 
than “typical” patients and, as a consequence, to perpetuate 
the gap between research and clinical practice.31,32 Patients 
with concurrent PD-SUD are also excluded because clinical 
studies have shown7,14 that such patients can be problematic, 
with a high dropout rate and a greater propensity to act 
violently (both in self-harm and acts of aggression against 
others). All of these factors could explain the tendency among 
professionals to refer these patients elsewhere.14 Neverthe-
less, several studies33–35 have shown that standard dialectical 
behavior therapy (DBT) can be effectively applied to patients 
with borderline PD (BPD) with or without comorbid SUD. 
Consequently, the exclusion of comorbid patients from 
specialized treatment may not be justified.
In a previous pragmatic study,27 we assessed a 6-month 
psychotherapeutic treatment for severe PD (mainly [78%] BPD 
patients) in a sample of patients with poor general functioning 
and a high prevalence of suicide attempts, self-harm behaviors, 
and comorbid SUD. In that study, we used a multicomponent 
integrated psychotherapeutic approach that combines effective 
techniques from various therapeutic models, primarily DBT 
and mentalization-based treatment (MBT). We found that this 
combined treatment was effective in preventing psychiatric 
inpatient readmissions and repeated psychiatric emergency 
room (ER) visits during the 6-month treatment period, a benefit 
that was maintained during the entire 36-month follow-up.
Given the scarcity of data on treatment outcomes in 
patients with PD-SUD, we carried out the present study to 
examine the following research questions: 1) Can a psy-
chotherapeutic program for patients with PD without SUD 
(PD-nSUD) be effectively applied to those with comorbid 
SUD (PD-SUD)? 2) Are there significant differences in treat-
ment outcome between PD patients with and without SUD?
Materials and methods
study and design
This study consists of a secondary analysis of data obtained 
in a previous pragmatic study.27 We carried out a pre–post, 
prospective, pragmatic study of patients admitted to an inte-
grated therapeutic program for PD with serious psychiatric 
symptomatology and low psychosocial functioning (severe 
PD). The study was conducted at a day hospital within the 
Barcelonès-Nord mental health network, a public health 
care catchment area that provides services to a population of 
approximately 299,000 inhabitants in the metropolitan area of 
Barcelona. Private practice in this area is scarce and limited 
to the outpatient setting. According to guidelines provided by 
the local health authorities, medical–psychiatric health care is 
sectorized, and patients should be referred to the appropriate 
hospital for their sector. Consequently, nearly all subjects 
with mental health disorders are referred to the only secto-
rial psychiatric hospital within the Barcelonès-Nord mental 
health network. The study was approved by the local Ethics 
Committee (Comité Etico de Investigación Clínica del Centre 
Emili Mira-Hospital Universitari Germans Trias i Pujol), and 
all patients signed an Informed Consent Form.
Participants and procedure
The sample was selected from all consecutive referrals to 
the severe PD program from September 2001 to December 
2006, inclusive. The inclusion criteria for admittance to the 
program were the following: 1) DSM-IV criteria36 for BPD; 
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or 2) DSM-IV criteria36 for another PD together with self-
inflicted lesions, suicidal behavior, or impulsive behavior 
($ two fields: spending, sex, substance abuse, reckless driv-
ing, and food binges) of the fourth DSM-IV criteria for BPD; 
3) a score of 50 or less in the Global Assessment of Func-
tioning (GAF) scale of DSM-IV;36 and 4) ability to initiate 
treatment without having to take a leave from studies or work. 
The exclusion criteria were as follows: presence of DSM-IV36 
criteria for 1) schizophrenia, 2) bipolar I disorder, 3) mental 
retardation, or 4) severe maladaptive behaviors associated 
with SUD that interfered seriously with treatment (eg, either 
highly aggressive behaviors such as frequent physical fights, 
or excessive time dedicated to SUD-related activities [such 
as obtaining, using, and/or recovering from the effects of the 
substance] such that attendance at the pretreatment assessment 
meetings was compromised). All patients were referred by a 
trained therapist after assessment involving a clinical inter-
view performed in accordance with the DSM-IV criteria.36 The 
assessment protocol included administration of the following: 
a sociodemographic survey, a psychiatric service use registry, 
a substance use questionnaire, drug urinalysis screening 
(cannabis, opiates, cocaine, amphetamine, LSD, and benzo-
diazepines), the DSM-IV GAF scale, and the Spanish version 
of the Structured Clinical Interview for DSM-IV Personality 
Disorders (SCID-II).37 Clinical severity was evaluated 
pragmatically according to the occurrence of crisis events, 
a composite of suicidal and self-harming behaviors and 
hospitalization, proposed by Bateman and Fonagy.19 These 
authors included hospital admission because patients are 
offered inpatient care in anticipation of suicide attempts and 
severe self-harm. We assessed when a patient presented one, 
two, or three of these events. Transient psychotic symptoms 
were assessed by clinical interview and the paranoid ideation 
criteria of the fourth DSM-IV for BPD.
The flow of participants through the study is shown in 
Figure 1. Of the patients assessed during the designated 
period, three were excluded because they met criteria 
for a diagnosis of schizophrenia (two cases) or bipolar I 
Figure 1 Flow of participants in the study.
Abbreviations: sciD-ii, structured clinical interview for DSM-IV personality disorders; PD, personality disorder; PD-sUD, personality disorder with comorbid substance 
use disorder; PD-nsUD, personality disorder without substance use disorder.
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disorder criteria (one patient). No patients were excluded for 
criterion 4 of the exclusion criteria. In 12 cases (admitted in 
2001 and 2002), it was not possible to administer the SCID-II 
because of problems related to the program launch. Thus, the 
final sample included 51 patients diagnosed with PD.
The SUD group was defined according to the following 
criteria: 1) DSM-IV criteria36 for SUD (alcohol, cannabis, 
opiates, amphetamine, LSD, or cocaine). Notably, benzodiaz-
epines, nicotine, and caffeine were not included because these 
SUD are not generally excluded in psychotherapy efficacy 
studies and 2) at least one positive drug urinalysis screening 
for cannabis, opiates, amphetamine, LSD, or cocaine in the last 
3 months (alcohol use was not considered). In the final sample, 
28 cases (54.9%) were included in the PD-SUD group and 
23 (45.1%) in the PD-nSUD group. Sixteen patients (31.4%) 
of the total sample prematurely dropped out of the program: 
eleven (39.3%) in the PD-SUD group and five (21.7%) in the 
PD-nSUD group. However, because the dropout rate did not 
differ significantly between the two groups (χ2=1.08; df=1; 
P=0.30), the patients who abandoned the program were 
included in the analysis. During the treatment period, one 
patient (PD-nSUD group) died as a result of self-inflicted 
lesions, and 17 months after finishing treatment, one patient 
(PD-SUD group) committed suicide; in both cases, the last 
observations were carried forward.
intervention: the integrated therapeutic 
program for severe PD
The treatment program, which has been described previ-
ously in detail,27 is a multicomponent, integrated treatment 
that adopts the four general therapeutic strategies suggested 
by Livesley38 as a general organizational framework and 
combines effective techniques from various evidence-based 
therapeutic models, such as DBT39 and MBT.40 The program 
offers 6 months of treatment, open to both male and female 
subjects aged 18–55 years. This is an open therapeutic pro-
gram; however, new patients are generally not allowed to join 
the program during the February to September time period 
to assure that the treatment program can be finalized either 
before (preferably) or during the month of July (members 
of the treatment team have a part-time dedication to the pro-
gram and there are strict limitations with regard to vacation 
time during the treatment period). All patients must have a 
confirmed diagnosis of a PD (usually BPD). Most patients 
have low general functioning and the presence of serious 
behavioral disorders, most commonly suicidal behavior and 
self-inflicted lesions. Before and after discharge, patients 
receive standard psychiatric treatment. The program, which 
takes place from Monday to Friday, comprises several weekly 
group interventions: 1) skills training (2.5 hours) based 
on DBT techniques;39 2) relationship therapy (1.5 hours), 
supported by MBT;40 3) stress management (2 hours); and 
4) psychoeducational therapy (1.5 hours). In addition, the 
program includes the following: 5) individual therapy once 
a week, consisting of support psychodynamic psychotherapy 
or DBT, depending on the therapist’s approach; 6) medication 
review; 7) nursing consultation; and 8) telephone consultation 
(from Monday to Friday, from 9:00 am to 4:00 pm). Group 
psychotherapy is conducted in cotherapy by nursing staff and/
or psychotherapists. Individual psychotherapy is conducted 
by a team of four psychotherapists with more than 10 years 
of training and extensive psychotherapeutic experience at 
public hospitals. Medication is based on a symptom-targeted 
approach41 and is prescribed by a psychiatrist from the treat-
ment team. Pharmacotherapy prioritizes antidepressant, 
mood stabilizers, and antipsychotic drugs; polypharmacy and 
benzodiazepines are discouraged. Once a week, the whole 
team holds a supervisory meeting (1.5 hours) to discuss the 
cases and the program.
Outcome variables
The main outcome variable was the need for psychiatric 
hospitalization, assessed in several ways: 1) as a proportion 
of psychiatric inpatient admissions treated as a dichoto-
mous variable (presence or absence of admissions); 2) as a 
count variable (number of admissions); and 3) as a continuous 
variable (days of hospitalization). Other outcome variables 
were 4) proportion of ER visits for psychiatric care, also 
assessed as a dichotomous variable (presence or absence of 
psychiatric ER visits) and 5) number of ER visits. Assess-
ments were made before admission to the program or base-
line assessment (T
0
, including the 6 months prior to starting 
treatment), after 6 months of treatment (T
1
), and every 
6 months until completion of the 36-month follow-up (T
2
, 
including months 7–12 from starting treatment; T
3
, months 
13–18; T
4
, months 19–24; T
5
, months 25–30; T
6
, months 
31–36). We searched the psychiatric hospital database (the 
only such database within the mental health network) to 
obtain information about hospitalizations and ER visits 
among the study sample before and during treatment and 
throughout the follow-up period. It is possible (although 
unusual) that a patient could have been treated at another 
hospital outside of our catchment area. Therefore, as a part 
of routine mental health assessment, patients were asked at 
the baseline interview about the use of psychiatric services, 
clinical report forms were requested, and, if appropriate, the 
data were verified with the mental health care professionals 
who treated the patient previously. Similarly, again as part 
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of routine procedures, during treatment at the day hospital, 
patients and their families were asked about the use of psy-
chiatric services. Finally, throughout the follow-up period, 
the professionals who treated the patients were asked about 
the use of psychiatric services by these patients; data were 
verified against the patient medical records.
statistical analyses
The analyses were performed with the SPSS® statistics pro-
gram (SPSS version 21.0; IBM Corporation, Armonk, NY, 
USA) and the R statistical software (version 3.1.2; https://
www.r-project.org/, The R Foundation, Vienna, Austria). 
Count and continuous variables were described by mean 
values and standard deviations, and categorical variables 
were defined by absolute frequencies and percentages, 
all of which were calculated for each group (PD-SUD vs 
PD-nSUD). Baseline characteristics were compared using 
chi-square statistics with Yates correction for dichotomous 
variables, the Mann–Whitney U-test for count variables, and 
the Student’s t-test for continuous variables after comparing 
the variances between the two samples. All outcome variables 
were analyzed on an intention-to-treat analysis. Values of 
P,0.05 were considered significant. To quantify the dif-
ference between the mean values of continuous outcome 
variables, the effect size was calculated as the difference 
between the baseline mean and the last mean (T
6
), divided 
by the baseline standard deviation.42
For the analysis of change throughout the follow-up, 
generalized estimating equation (GEE) was used, a procedure 
that goes beyond the generalized linear model for the analysis 
of repeated measures. GEE takes into account that the same 
patients are repeatedly measured and uses all the available 
data, irrespective of the number of repeated measurements.43 
We performed a GEE analysis with each of the outcome mea-
sures as dependent variables and time (continuous), SUD, 
and the interaction time × SUD as independent variables. 
Therefore, GEE logistic (outcomes 1 and 4), Poisson 
(outcomes 2 and 5), and Gaussian (outcome 3) regressions 
were performed. To reduce variances attributed to nonrel-
evant factors, age and sex were included as covariates. A 
likelihood ratio test was applied to determine whether the 
model fitted better when interactions were included in the 
model.
Results
sample description
Differences between sociodemographic characteristics were 
not significant (Table 1) except for the fact that the PD-SUD 
Table 1 Baseline demographic and clinical characteristics
Variable PD-SUD (n=28) PD-nSUD (n=23) χ2 P-value
n % n %
Female 16 57.1 15 65.2 0.09 0.77
Never married 17 60.7 11 47.8 0.41 0.52
living with family of origin 22 78.6 12 52.2 2.86 0.10
less than high school (education) 15 53.6 15 65.2 0.31 0.58
statutory sick/disability pension 13 46.4 14 60.9 0.56 0.45
suicide attempts 23 82.1 18 78.3 0.00 1.00
self-harming behavior 17 60.7 16 69.6 0.13 0.72
aggression episodes 12 42.9 4 17.4 2.71 0.10
Transient psychotic symptoms 15 53.6 8 34.8 1.12 0.29
any mood disorder 25 89.3 20 87.0 0.00 1.00
any anxiety disorder 19 67.9 16 69.6 0.00 1.00
Borderline personality disorder 23 82.1 17 73.9 0.14 0.71
Psychiatric inpatient admission (T0) 22 78.6 10 43.5 5.24 0.02
Psychiatric er visit (T0) 22 78.6 9 39.1 6.67 0.01
Mean SD Mean SD t or z P-value
age at start of treatment 30.5 6.8 36.9 10.7 -2.47 0.02
Age at first psychiatric inpatient admission 25.6 5.7 30.8 10.6 -1.83 0.08
Age at first psychiatric consultation 19.6 8.9 20.3 10.5 -0.26 0.80
Time since first consultation, years 10.9 7.2 16.5 10.1 -2.26 0.03
gaF scale 37.9 4.2 40.9 4.2 -2.53 0.02
Number of psychiatric admissions (T0) 1.7 1.4 0.6 0.9 3.09 0.00
Days of psychiatric hospitalization (T0) 35.9 31.9 13.7 21.2 2.97 0.00
Number of psychiatric er visits (T0) 2.5 2.3 0.8 1.3 3.18 0.00
Abbreviations: gaF, global assessment of Functioning; PD-sUD, personality disorder with comorbid substance use disorder; PD-nsUD, personality disorder without 
substance use disorder; sD, standard deviation; er, emergency room.
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group was younger. Similarly, PD-SUD patients were also 
younger at the first psychiatric admission and had more pre-
vious psychiatric hospitalizations and psychiatric ER visits. 
All patients reported at least one crisis event (suicidal or 
self-harming behavior, or hospitalization). Fourteen patients 
(50.0%) in the PD-SUD group and five patients (21.7%) in the 
PD-nSUD group (χ2=3.19; df=1; P=0.07) reported three crisis 
events, and nine patients (32.1%) in the PD-SUD group and 
12 patients (52.2%) in the PD-nSUD group (χ2=1.35; df=1; 
P=0.25) reported two crisis events. Although the PD-SUD 
group presented more behavioral disorders, transient psy-
chotic symptoms, and a higher proportion of BPD diagnoses, 
these differences were not significant. However, the PD-SUD 
group had a significantly lower GAF score (Table 1). At baseline, 
28 patients (100%) in the PD-SUD group and 22 patients (95.7%) 
in the PD-nSUD group (χ2=0.01; df=1; P=0.92) reported that 
they were taking psychotropic medications. SUD consisted of 
the following use disorders: alcohol (20 patients; 71.4%), canna-
bis (19 patients; 67.9%), cocaine (16 patients; 57.1%), amphet-
amine (four patients; 14.3%), and opioid (three patients; 10.7%). 
In addition, 19 patients (67.9%) used two or more substances; 
eleven patients (39.3%) met criteria for dependence on at 
least one substance.
Outcome variables
There was a significant reduction (P,0.001) across time 
(Table 2) in the five outcome variables (the proportion 
and the number of psychiatric inpatient admissions, days 
of hospitalization, and the proportion and the number of 
psychiatric ER visits). This indicates that the treatment was 
effective in reducing psychiatric hospitalizations and psychi-
atric ER visits, a benefit that was maintained during the entire 
36-month follow-up. Comparatively (Table 2), PD-SUD 
patients suffered more psychiatric hospitalizations and ER 
visits than PD-nSUD patients during the 36-month follow-up 
(Figures 2 and 3). However, the differences between these 
two groups were stable over time as shown by the interaction 
time × SUD (Table 2), which was not significant in four of 
the outcome variables: the proportion of psychiatric inpatient 
admissions, number of psychiatric inpatient admissions, 
proportion of psychiatric ER visits, and number of psychi-
atric ER visits. These findings show that the treatment was 
equally effective in both groups as measured by these specific 
outcome variables. Conversely, the interaction time × SUD 
(Table 2) differed significantly for the number of days of 
hospitalization, as the difference between the two groups 
decreased significantly over time, meaning that the treat-
ment was more effective for the PD-SUD patients in which 
the duration of hospitalization decreased significantly. The 
effect size for the PD-SUD group was higher (d =0.94) than 
that for the PD-nSUD group (d =0.62).
Discussion
In this study, our main aim was to determine treatment out-
comes in patients with concurrent SUD and PD who under-
went a multicomponent treatment approach that integrates 
Table 2 Outcome variables: analysis of change throughout the 36-month follow-up
Psychiatric hospitalization
Inpatients (proportion of admissions) Number of admissions Days of hospitalization
B (SE) P-value OR (95% CI) B (SE) P-value 95% CI of B B (SE) P-value 95% CI of B
(intercept) -0.57 (0.99) 0.56 0.56 (0.08/3.91) -1.32 (0.75) 0.08 -2.79/0.14 9.62 (5.24) 0.07 -0.65/19.90
Time -0.32 (0.07) 0.00 0.73 (0.63/0.84) -0.24 (0.07) 0.00 -0.38/-0.11 -1.28 (0.45) 0.00 -2.16/-0.40
sUD 1.03 (0.42) 0.02 2.81 (1.22/6.45) 1.08 (0.33) 0.00 0.43/1.73 14.18 (4.28) 0.00 5.79/22.56
sex 0.83 (0.37) 0.03 2.28 (1.10/4.75) 0.66 (0.29) 0.02 0.10/1.22 5.84 (2.63) 0.03 0.68/10.99
age -0.03 (0.03) 0.32 0.97 (0.93/1.03) -0.00 (0.02) 0.86 -0.04/0.04 -0.16 (0.13) 0.21 -0.40/0.09
Time:sUD -0.01 (0.16) 0.97 0.99 (0.73/1.35) -0.01 (0.16) 0.97 -0.31/0.30 -2.15 (0.76) 0.00 -3.64/-0.67
Psychiatric emergency room visit
Patients (proportion of ER visits) Number of ER visits
B (SE) P-value OR (95% CI) B (SE) P-value 95% CI of B
(intercept) 0.26 (0.81) 0.75 1.29 (0.26/6.35) -0.19 (0.54) 0.73 -1.25/0.87
Time -0.18 (0.05) 0.00 0.84 (0.75/0.93) -0.14 (0.04) 0.00 -0.22/-0.06
sUD 0.81 (0.35) 0.02 2.25 (1.14/4.43) 0.84 (0.25) 0.00 0.36/1.33
sex 0.87 (0.37) 0.02 2.39 (1.16/4.92) 0.59 (0.30) 0.05 0.01/1.17
age -0.04 (0.02) 0.13 0.97 (0.92/1.01) -0.02 (0.02) 0.37 -0.05/0.02
Time:sUD 0.03 (0.11) 0.81 1.03 (0.82/1.29) 0.00 (0.10) 0.97 -0.19/0.19
Note: B (eta), estimate.
Abbreviations: se, standard error; P, P-value; OR, odds ratio; CI, confidence interval; SUD, substance use disorders; Time:SUD, time × sUD interaction; er, emergency 
room.
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effective techniques borrowed from therapeutic models 
including both DBT and MBT. Our findings indicate that 
this treatment approach significantly reduced psychiatric 
inpatient readmissions and repeated psychiatric ER visits 
in patients with comorbid SUD-PD and in patients with 
PD alone. Importantly, these benefits were achieved in a 
sample of patients with severe PD (primarily BPD) who had 
poor general functioning and a high prevalence of suicide 
attempts and self-harm behaviors. In addition, these gains 
were maintained during the 36-month follow-up. These find-
ings suggest that PD patients with concurrent SUD should 
not be excluded from psychotherapeutic interventions given 
that treatment outcomes in this group are equally as good as 
in patients with PD alone.
Based on the available evidence,2,44 PD-SUD patients 
are younger, have lower levels of education, are less likely 
to be married, have more severe psychopathology, and are 
more impulsive than patients with PD-nSUD. However, in 
our study, although the PD-SUD group was younger, dif-
ferences in other sociodemographic characteristics were 
not significantly different from the PD-nSUD group. Not 
surprisingly, PD-SUD patients had received more previous 
psychiatric inpatient treatment, which has been associated 
with the PD severity in patients admitted for treatment,19,23,27 
presented more crisis events, and also had a lower GAF score. 
Objective severe symptoms (ie, suicidal and self-harming 
behaviors), together with (as in other studies19,20,22,24,45) data 
on the patient’s overall level of functioning (GAF), provide 
Figure 2 changes in psychiatric hospitalizations (36 months).
Notes: T0: it includes the 6 months before treatment start; T1: it includes the 6 months of treatment; T2: months 7–12 from treatment start; T3: months 13–18; T4: months 
19–24; T5: months 25–30; T6: months 31–36.
Abbreviations: PD-sUD, personality disorder with comorbid substance use disorder; PD-nsUD, personality disorder without substance use disorder.
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a longitudinal and comprehensive clinical assessment in 
patients characterized by high levels of impulsivity and insta-
bility whose symptoms could change in a matter of hours. 
Although the PD-SUD patients presented more behavioral 
disorders and transient psychotic symptoms, these differences 
were not significant, probably because of the high propor-
tion of patients in both groups with BPD. Nevertheless, the 
baseline prevalence of self-aggressive and heteroaggressive 
behavior and transient psychotic symptoms in the PD-SUD 
group in this study was among the highest reported in stud-
ies that have assessed the efficacy of psychotherapeutic 
interventions for PD.17–26,29,30,33,35 Given that our sample 
consisted of patients with severe disorders (with low levels 
of global functioning), the good results in terms of efficacy 
of our psychotherapeutic approach cannot be attributed to 
low-severity disorders.
The main conclusion of the study is that specialized 
psychotherapy for severe PD can be effectively applied to 
PD patients with concurrent SUD. Importantly, our find-
ings suggest that the treatment effect size may be higher in 
patients with dual disorders compared to PD patients who do 
not suffer from SUD. These findings have important clinical 
implications, as they strongly suggest that the traditional 
practice of excluding these dual patients from treatment in 
specialized psychotherapy studies does not seem justified and 
may, therefore, reduce the external validity of such studies 
because of sample bias. Furthermore, these findings indicate 
that evidence-based psychotherapy approaches for severe PD 
should be made available to PD-SUD patients as part of the 
usual mental health clinical care practice. Unlike many studies, 
we did not exclude any of the PD-SUD patients during the 
assessment process.
We believe that the good results in terms of accessibility 
described in our study can be explained, at least in part, by 
specific management and clinical factors. Prior to launch-
ing the program, an informational session about the study 
Figure 3 changes in psychiatric emergency room visit (36 months).
Notes: T0: it includes the 6 months before treatment start; T1: it includes the 6 months of treatment; T2: months 7–12 from treatment start; T3: months 13–18; T4: months 
19–24; T5: months 25–30; T6: months 31–36.
Abbreviations: PD-sUD, personality disorder with comorbid substance use disorder; PD-nsUD, personality disorder without substance use disorder.
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objectives was held in each of the three mental health centers 
that serve the community area. During this meeting, inclusion 
and exclusion criteria were thoroughly discussed, and we 
clearly specified that the goal of the program was to make the 
program as accessible as possible (although we also explained 
the circumstances under which treatment was not appropriate). 
The flow of participants through the study (Figure 1) showed 
that 14 of patients referred for treatment did not attend any 
assessment interview and were therefore not admitted to 
treatment. We do not have accurate information about the 
percentage of nonattending patients who also had concurrent 
SUD because the only information available was the referral 
report form. However, several authors7,14,46 have pointed out 
the difficulties in engaging the more disturbed SUD patients 
in structured therapeutic programs. Therefore, one possible 
hypothesis for why we did not exclude from the study any 
of the PD-SUD patients could be that the referring physi-
cians accurately described the treatment program and this 
may have dissuaded the more behaviorally disturbed SUD 
patients from attending the assessment interview.
Our results are consistent with the findings previously 
reported in other studies. Two studies33,35 showed that stan-
dard DBT can be effectively applied in patients with BPD 
and comorbid SUD (although it should be noted that these 
studies included only female patients). However, in contrast 
to our study, those two studies did not evaluate psychiatric 
hospitalizations and ER visits – both of which are well-known 
pragmatic variables that often reveal worse outcomes in 
SUD patients.46
The results of our study at 36 months also seem to indicate 
that the beneficial effects of this treatment may be long-
lasting, even in patients with severe disorders. Moreover, 
these benefits were confirmed by objective outcome mea-
sures rather than subjective measures. Obviously, sustained 
recovery in our group cannot be attributed solely to the PD 
intervention, but it seems likely that standard psychiatric 
treatment after completion of this program would be more 
effective than before.27
This study has several limitations. The main limitation is 
the lack of a control group. As a result, the outcomes reported 
here may only show the course of PD in this treatment setting. 
However, the results of the only RCT with long-term follow-up 
conducted at a day hospital in a PD sample whose severity 
and psychosocial functioning (mean GAF #40) was similar 
to that of our study23,24,45 found that the need for psychiatric 
hospitalization in patients who followed treatment as usual 
did not improve gradually over time, rather it worsened and 
was highly irregular. Thus, the proportion of psychiatric 
inpatient admissions in patients under treatment as usual 
24, 30, and 36 months after treatment initiation was 36.8%, 
36.8%, and 73.7%, respectively.47 Another limitation of our 
study is related to difficulties in reliably monitoring suicide 
attempts and substance use throughout the entire 36-month 
follow-up, as resource limitations made this unfeasible. 
However, the frequency of hospitalization episodes and 
ER visits is a reasonable approximation of serious suicidal 
behavior and severe self-harm acts.19,45 In fact, patients are 
offered hospitalization in anticipation of suicide attempts 
and severe self-harm,19 which, in many cases, would prevent 
these behaviors. Nevertheless, a reduction in hospitalizations 
and ER visits does not assure an overall clinical improve-
ment and cannot in any way be considered the only purpose 
of severe PD patient treatment. However, this is a rational 
approach that allows a pragmatic assessment of clinical 
progress or worsening of severe PD. Finally, the relatively 
small sample size of this study is a limitation, although it is 
worth mentioning that the sample size was comparable to one 
of the other studies in the literature that assessed the efficacy 
of psychotherapeutic interventions for PD.16,32
In contrast to the aforementioned limitations, our study 
also has several important strengths related to its pragmatic 
design, treatment accessibility for SUD patients, the use of 
objective outcome measures (hospitalizations and ER visits), 
and the long (3 years) follow-up period. In this sense, the 
Cochrane Review16 has pointed out that it is necessary to 
replicate the results of RCTs of BPD in “real-world” studies. 
Likewise, several authors16,24,31,32 have argued that pragmatic 
studies are needed in severe PD to determine whether the 
treatment efficacy found in controlled studies can be rep-
licated under usual practice conditions, and this is what 
we have done in the present pragmatic study.32,48 Another 
strength of our study is that data were collected as part of the 
usual mental health care routine, a fact that further reinforces 
the external validity of the study.
Despite the good results of this study, much more research 
is needed to develop specialized programs tailored for this 
difficult-to-treat population, and such programs should be 
implemented according to therapeutic strategies based on 
evidence-based interventions.49 It might be beneficial to 
consider programs designed for patients with PD and specific 
SUD (eg, PD + alcohol, cocaine, or opiate use disorder).50
Conclusion
The results of this study demonstrate that, under usual prac-
tice conditions, specialized psychotherapy for severe PD can 
be effectively applied in PD patients with comorbid SUD 
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and that the benefits of this intervention can last for long 
periods of time (36 months in this study). These results are 
consistent with, and thus provide further support for, previ-
ously reported findings. The available data from this study 
and others strongly suggest that patients with dual PD-SUD 
should not be excluded from specialized psychotherapy 
studies. Moreover, PD-SUD patients should have access to 
treatment approaches such as the one used in this study as 
part of the usual mental health care routine.
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